Form 4/A for SOPH SOPHiA GENETICS SA

Accepted 2026-04-08 08:47:01 ET · period of report 2026-04-02 · accession 0001840706-26-000105 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DA	2026-04-08 08:47	2026-04-02	SOPH	Puylaert Kevin	Chief Sales Off	A - Grant	$0.00	+56.5K	148.9K	+61%	$0
DA	2026-04-08 08:47	2026-04-02	SOPH	Puylaert Kevin	Chief Sales Off	A - Grant	$0.00	+82.3K	82.3K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2026-04-02	A	A	56,468	$0.00	148,854	D	—	—	(F1) Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. (F2) This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 56,468 ordinary shares due to an inadvertent error. The correct amount is 148,854 ordinary shares.
2	Derivative	Share Option (Right to Buy)	2026-04-02	A	A	82,335	$0.00	82,335	D	$5.04 · — to 2036-04-02	82,335 Ordinary Shares	(F3) The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.